Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immune-Related Adverse Events (irAEs) in Advanced NSCLC Patients Treated With Atezolizumab: Safety Population Analyses From the Ph III Study OAK

Date

09 Sep 2017

Session

Poster display session

Presenters

Diego Cortinovis

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

D. Cortinovis1, J. von Pawel2, K. Syrigos3, J. Mazieres4, R. Dziadziuszko5, L. Fehrenbacher6, P. Conkling7, J. Goldschmidt8, C.A. Thomas9, R. Bordoni10, M. Kosty11, F.S. Braiteh12, P. He13, M. Ballinger14, M. Gandhi15, H. Patel16, D.R. Gandara17

Author affiliations

  • 1 Medical Oncology Unit, AOU San Gerardo, 20900 - Monza/IT
  • 2 Thoracic Oncology, Asklepios-Fachkliniken München-Gauting, Gauting/DE
  • 3 3rd Department Of Medicine, Athens School of Medicine, Athens/GR
  • 4 Thoracic Oncology Department, Toulouse University Hospital, Toulouse/FR
  • 5 Department Of Oncology And Radiotherapy, Medical University of Gdansk, Gdansk/PL
  • 6 Oncology, Kaiser Permanente Medical Center, Vallejo/US
  • 7 Medical Oncoloy, Virginia Oncology Associates, Norfolk/US
  • 8 Clinical Research, Blue Ridge Cancer Care, Blacksburg/US
  • 9 Medical Oncoloy, New England Cancer Specialists, Scarborough/US
  • 10 Medicine, Georgia Cancer Specialists; Northside Hospital Cancer Institute, Atlanta/US
  • 11 Division Of Hematology/oncology, Scripps Clinic, La Jolla/US
  • 12 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 13 Biostatistics, Genentech, Inc., South San Francisco/US
  • 14 Product Development Oncology, Genentech, South San Francisco/US
  • 15 Usma, Genentech, Inc., South San Francisco/US
  • 16 Product Development Safety Science, Genentech, South San Francisco/US
  • 17 Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento/US
More

Resources

Background

A superior survival benefit with atezolizumab (atezo; anti–PD-L1) vs docetaxel (doc; HR 0.73; 95% CI: 0.62, 0.87) has been demonstrated in OAK, the first randomized Ph III study of atezo in NSCLC patients (pts) who had failed prior platinum therapy. In the primary efficacy population (n = 850), atezo benefit was seen regardless of PD-L1 expression levels on tumor cells (TC) or tumor-infiltrating immune cells (IC). Here, we present the analyses of irAEs in the safety population (N = 1225) of OAK.

Methods

Pts were randomized 1:1 to atezo (1200 mg) or doc (75 mg/m2) IV q3w. Co-primary endpoints were OS in ITT and in PD-L1 expression subgroups. Secondary endpoints included ORR and safety. irAEs were defined using MedDRA Preferred Terms that included both diagnosed immune conditions and signs and symptoms potentially representative of immune related events, regardless of investigator-assessed causality. Safety analyses conducted were incidence, nature and severity of irAEs, corticosteroid use and irAEs leading to atezo interruption/discontinuation. Data cutoff: July 7, 2016.

Results

In the atezo arm, 6.2% of pts had grade 3-4 irAEs and 25.0% of pts had grade 1-2 irAEs. No grade 5 irAEs were reported. Low rates of any-grade hypothyroidism (3.9%), pneumonitis (1.5%), hepatitis, (1.1%), and colitis (0.3%) were observed. Grade 3-4 irAEs included pneumonitis (0.7%) and hepatitis (0.7%); no pts developed Grade 3-4 colitis. 36 (5.9%) atezo arm pts experienced irAEs requiring corticosteroid treatment. Majority of irAEs in the atezo arm were manageable; 13 pts (2.1%) discontinued atezo. Meningoencephalitis (0.7%) and AST/ALT elevation (0.3%/0.2%) were the most frequently reported irAEs leading to atezo discontinuation. 26 pts (4.3%) had dose interruptions due to irAEs. AST/ALT elevation (0.8%/0.8%) and diarrhea (0.8%) were the most frequently reported irAEs leading to dose interruption.

Conclusions

The irAEs occurring in atezo-treated pts were mostly low grade and manageable, with few pts requiring dose interruption/discontinuation of atezo and corticosteroid treatment. Efficacy data based on irAE subgroups of OAK are presented separately.

Clinical trial identification

NCT02008227

Legal entity responsible for the study

F. Hoffmann - La Roche Ltd.

Funding

F. Hoffmann - La Roche Ltd.

Disclosure

D. Cortinovis: Membership for AB for Roche, Novartis, MSD, BI. J. von Pawel: Adboard: AbbVie, Pfizer, Bristol Myers Squibb, Novartis money paid to the institution. R. Dziadziuszko: Honoraria or consulting fees from Roche, Pfizer, Boehringer‐Ingelheim, Clovis Oncology, Novartis, Astra‐Zeneca, Tesaro. P. Conkling: research funding is US Oncology Research. J. Goldschmidt: Honoraria: Amgen Consulting/Advisory Role: Amgen Speakers Bureau: Bristol Myers‐Squibb, Celgene. M. Kosty: Support limited to Institutional support for the reported trial and other clinical trials. No direct compensation to investigator. No other conflicts to report. F.S. Braiteh: COI: speaking and consulting fees received from Genentech. P. He: Employee of Roche/Genentech, and have stocks for Roche, Amgen. Husband has stocks for Allergan and Gilead. M. Ballinger: Employee of Genentech, Roche stock. M. Gandhi: Employee of Genentech. H. Patel: Genentech Employee. D.R. Gandara: Consultant: Genentech Clinical trial grant: Genentech. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings